# Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

> **NCT07645534** · PHASE1 · RECRUITING · sponsor: **Valenta Pharm JSC** · enrollment: 36 (estimated)

## Conditions studied

- Influenza
- Acute Respiratory Viral Infections

## Interventions

- **DRUG:** Ingavirin forte, capsules, 90 mg + 20 mg
- **DRUG:** Ingavirin, capsules, 90 mg

## Key facts

- **NCT ID:** NCT07645534
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-11
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645534, "Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07645534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*